S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

$20.52
+0.72 (+3.64%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$19.28
$20.57
50-Day Range
$16.49
$27.64
52-Week Range
$16.20
$28.95
Volume
267,152 shs
Average Volume
333,670 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41
30 days | 90 days | 365 days | Advanced Chart
Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
143
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.08 million
Book Value
$5.66 per share

Profitability

Net Income
$-107.64 million
Pretax Margin
-2,812.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,547,000
Market Cap
$1.10 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
3/30/2022
Today
5/21/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

348th out of 1,416 stocks

Pharmaceutical Preparations Industry

136th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -













Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 2,180,000 shares, a drop of 18.0% from the April 15th total of 2,660,000 shares. Based on an average daily trading volume, of 277,300 shares, the days-to-cover ratio is presently 7.9 days.
View Crinetics Pharmaceuticals' Short Interest
.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings data on Wednesday, March, 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.05.
View Crinetics Pharmaceuticals' earnings history
.

What price target have analysts set for CRNX?

7 equities research analysts have issued 12-month price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $37.20 in the next twelve months. This suggests a possible upside of 81.3% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?
Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers Ph.D., Founder, Pres, CEO & Director (Age 59, Pay $820.33k)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 42, Pay $527.72k)
  • Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 59)
  • Dr. Stephen F. Betz Ph.D., Founder & Chief Scientific Officer (Age 56)
  • Mr. Jeff E. Knight, Chief Operating Officer
  • Ms. Garlan Adams, Gen. Counsel
  • Ms. Adriana Cabre M.B.A., Chief HR Officer
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 59)
  • Mr. Kevin Capps, Head of Intellectual Property
  • Mr. James Hassard, Chief Commercial Officer (Age 55)
What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.90%), Vanguard Group Inc. (4.39%), State Street Corp (3.56%), Deep Track Capital LP (3.23%), Frazier Life Sciences Management L.P. (2.96%) and Wellington Management Group LLP (2.15%). Company insiders that own Crinetics Pharmaceuticals stock include Ajay Madan, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends for Crinetics Pharmaceuticals
.

Which major investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Invesco Ltd., Wellington Management Group LLP, Citigroup Inc., Ghost Tree Capital LLC, Northern Trust Corp, Metropolitan Life Insurance Co NY, and Royal Bank of Canada. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Ajay Madan, Matthew K Fust, Richard Scott Struthers, and Stephen F Betz.
View insider buying and selling activity for Crinetics Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Novo Holdings A S, State Street Corp, First Light Asset Management LLC, First Manhattan Co., Dimensional Fund Advisors LP, Walleye Capital LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $20.52.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $1.10 billion and generates $1.08 million in revenue each year. The company earns $-107.64 million in net income (profit) each year or ($2.840010) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 143 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.